February 19, 2009 — Tibolone (Livial, Schering-Plough) — a synthetic steroid used to treat vasomotor symptoms and prevent bone loss — should not be prescribed to any woman with current, past, or ...

Buenos Aires, Argentina and Utrecht, the Netherlands - Tibolone (Livial, Organon), a synthetic steroid that relieves menopausal symptoms, has shown conflicting results on cardiovascular parameters in ...

Learn everything you need to know about Tibolone-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings, ...

Women treated with adjuvant therapy for breast cancer often experience vasomotor symptoms and bone loss as complications. The synthetic steroid, tibolone, is used to prevent these adverse effects but ...

Review the side-effects of Tibolone as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

To the Editor: In a randomized study of the effect of tibolone on fracture rates among postmenopausal women between the ages of 60 and 85 years, Cummings et al. (Aug. 14 issue) 1 report that tibolone ...

This Practice Point commentary discusses a double-blind, placebo-controlled trial by Cummings et al. that investigated the effects of tibolone 1.25 mg per day in 4,534 postmenopausal women (mean age ...

Long-term effect in outcomes of intensified primary chemotherapy in poor prognosis LABC T4 patients: Results of a multicenter Italian study ...

Women with a history of breast cancer could be risking their lives by taking a synthetic steroid drug commonly used to treat menopausal symptoms, it emerged today. Experts warned them to stay away ...

Tolerability and efficacy of classical CMF (cCMF) using oral cyclophosphamide (OC) vs intravenous cyclophosphamide (IVC) in early stage breast cancer: A non-randomised comparison of patients (pts) ...

MISSISSAUGA, Ontario, Sept. 20, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc., has ...